Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231725 · ClinicalTrials.gov registry record · Phase 3
Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 370
- Enrollment target
NCT00231725 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 370 participants.
The verdict
NCT00231725, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 370 participants
- Enrollment target
Study Summary
Trial of new insulin injection pen called Pre-filled Pen B by type 2 diabetics in take home situations. Patients must use insulin lispro injection \[rDNA origin\] Low Mix twice daily during the trial.
Interventions
- DRUG insulin lispro injection [rDNA origin] Low Mix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 370 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231725
The ClinicalTrials.gov registry entry for NCT00231725 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 370 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which insulin lispro injection [rDNA origin] Low Mix is the first listed.
NCT00231725 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231725 about?
NCT00231725 is a clinical study titled "Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin". Trial of new insulin injection pen called Pre-filled Pen B by type 2 diabetics in take home situations. Patients must use insulin lispro injection \[rDNA origin\] Low Mix twice daily during the trial.
What is the current status of trial NCT00231725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 370 participants. The study started on 2005-09. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00231725?
The interventions under investigation include: insulin lispro injection [rDNA origin] Low Mix (DRUG).
Who is sponsoring clinical trial NCT00231725?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.